The combination of ivosidenib and azacitidine revealed a manageable safety profile and quality of life profile in patients with IDH1-mutant acute myeloid leukemia in the phase 3 AGILE study.
Results from the phase 3 ARCHES trial confirm the survival benefit of enzalutamide plus androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer.
For Head and Neck Cancer Awareness Month, Robert L. Ferris, MD, PhD, FACS, elaborated on the significant progress in the head and neck cancer space, as well as potentially practice-changing results that will come with emerging agents In an interview with Targeted Oncology™.
Results from the melanoma cohort the MATINS trial will be shared at the 18th Congress of the European Association of Dermato-Oncology.
In the FIGHT-101 study, clinical activity was demonstrated with pemigatinib in patients with FGF/FGFR-altered tumors.
A recent study looked into where time-to-next therapy and overall survival with immune checkpoint inhibitors were longer compared with taxane therapy, in patients with metastatic castration-resistant prostate cancer.
The FDA has granted approval to the biologics license application for bevacizumab-maly, a biosimilar of bevacizumab.
Treatment with PT-112 has begun in a phase 2 study of patients with thymoma and thymic carcinoma.
Barriers to improving BRAF testing turnaround time in patients with melanoma have been identified in a retrospective analysis of real-world data collected in Canada.
High risk human papillomavirus infection appears to be a strong determinant of cervical cancer prognosis over 15 years after diagnosis.
Treatment with nivolumab plus chemotherapy was more effective compared with chemotherapy alone in patients with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma in the CheckMate 649 study.
According to 5-year survival data from the BILCAP study, capecitabine stands up to observation as a treatment strategy for patient with biliary tract cancer.
Leuprolide 42 mg injection emulsion for the treatment of adult patients with advanced prostate cancer has launched in the United States.
In a small safety run-in analysis, no safety concerns were reported with frontline pelareorep in patients with metastatic colorectal cancer.
Selpercatinib is a promising treatment option for Chinese patients with RET-altered thyroid cancer, according to LIBRETTO-321 results.
In surveys conducted between 2020 and 2021, Cardinal Health sought to determine oncologists’ perceptions about their use of biosimilars in their treatment regimens.
Results from the phase 1b EQUATE study were favorable enough to initiate a phase 3 study, which will test itolizumab for the frontline treatment of acute graft-versus-host disease..
Researchers found that depletion of naïve T cells from peripheral blood stem cell allografts results in very low incidences of severe acute and chronic graft-versus-host disease without reduced risk of relapse or nonrelapse mortality.
With larotrectinib treatment, patients with advanced lung cancers whose tumors harbor NTRK gene fusions experienced durable responses, survival benefit, and a favorable safety profile.
Findings presented during the SGO Annual Meeting show that atezolizumab given prior to concurrent chemoradiation may be safe with immune modulating activity in patients with node-positive, locally advanced cervical cancer.
An announcement, made on February 2, 2022, heralded the return of an initiative begun under President Barack Obama in 2016, when President Biden was vice president.
The combination of brentuximab vedotin plus cyclophosphamide, doxorubicin, and prednisone bests the CHOP regimen in the treatment of patients with peripheral T-cell lymphoma.
The developer has announced that half of the patients are now enrolled in the BESPOKE CRC clinical trial.
Findings from the GALAHAD clinical trial highlight the importance of molecular testing to inform treatment and disease management decision for prostate cancer.
In the REFINE trial treatment with navitoclax to ruxolitinib in patients with myelofibrosis, spleen reduction has been observed.
The NCCN guidelines for myeloproliferative neoplasms now include ropeginterferon alfa-2b, which was recently granted FDA approval for the treatment of polycythemia vera.
According to retrospective data, racial disparities among patients being screened for lung cancer have decreased.
Results from the WINDOW-1 signal promise for use of the R-HCVAD regimen in patients with mantle cell lymphoma.
In a presentation Eytan M. Stein, MD, reported on single agent inhibitors followed by methods to overcome resistance using combination therapy.